The safety profile of oral semaglutide remains consistent with the expected effects of the GLP-1 receptor agonist class, even when used with PPIs like omeprazole
The anti-inflammatory pathways modulated by GLP-1 receptor activation (NF-kB suppression, macrophage polarization, Treg enhancement) are largely distinct from the pathways targeted by: Methotrexate: Folate metabolism disruption, different anti-inflammatory pathway TNF inhibitors (adalimumab, etanercept): Direct TNF blockade, whereas GLP-1 reduces TNF production upstream IL-6 inhibitors (tocilizumab): Receptor-level blockade, while GLP-1 reduces IL-6 production JAK inhibitors (tofacitinib, baricitinib): Different signaling pathway entirely Corticosteroids: Broad immunosuppression, while GLP-1 is immunomodulatory This pathway complementarity is why additive benefit is biologically plausible
Wegovy, however, comes as a single-dose auto-injector with a built-in needle that cannot be changed
Insurance and Cost Considerations This is often the entire reason for the switch, so its worth understanding the nuances
Speaking with your doctor about over-the-counter and prescription medications that may help you manage side effects, potentially only on a short-term basis
Feidantsis K, Methenitis S, Ketselidi K, Vagianou K, Skepastianos P, Hatzitolios A, et al
